Research · Sep 3, 2026
[ATR] AptarGroup Thesis 2026: Pharma Drug Delivery Drives Dispensing Closures Capital Return
AptarGroup, Inc. (NYSE: ATR) FY2025 revenue ~$3.55-3.75B (+3-7%) with adj. EPS ~$5.65-6.20 reflecting continued post-2024 ~$3.55-3.75B aggregate Pharma + Beauty + Closures dispensing solutions revenue (~$1.70-1.80B aggregate Pharma + ~$1.25-1.35B aggregate Beauty + ~$0.55-0.60B aggregate Closures) under continued President + CEO Stephan Tanda since 2018 (~7-year tenure as AptarGroup CEO; selected post-2018 succeeded Steve Hagge retirement). One of the largest US specialty Pharma + Beauty + Closures dispensing solutions companies. Founded 1940 as Calmar in Crystal Lake Illinois (~85-year heritage; selected pioneer Pharma + Beauty + Closures dispensing solutions specialty; selected post-1992 AptarGroup reorganization); selected post-April 1993 NYSE IPO via Pittway demerger; selected post-1993-2025 ~$3B+ cumulative tuck-in M&A platform expansion (Emsar Brescia 2002 + CSP Technologies Active Material Science 2018 $555M+ + Nanopharm 2019); selected post-2018 Stephan Tanda CEO appointment; selected post-2024 Pediatric Naloxone Nasal Spray + GLP-1 Auto-Injector + Pre-filled syringe boom. Headquartered in Crystal Lake Illinois; ~12,000-13,000 employees globally. Three primary segments: Pharma ~48%+ ($1.70-1.80B), Beauty + Home ~35%+ ($1.25-1.35B), Closures ~16%+ ($0.55-0.60B). Geographic mix: North America ~35%+ + Europe ~40% + Asia Pacific ~20% + selected various aggregate ~5%. Pharma Drug Delivery + Active Material Science pipeline (~$1.70-1.80B): ~$1.70-1.80B Pharma revenue (~48%+); selected primary Prescription Drug Delivery + Inhalation (MDI + DPI) + Nasal Spray (Nasonex + Flonase + post-2024 Narcan Pediatric Naloxone) + Injectables (Auto-Injectors + Pre-filled syringes); selected ~$130-150B global Pharma Dispensing TAM; selected ~$100-150 Pharma value per device; selected post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom + Pediatric Naloxone Nasal Spray growth. Beauty + Home + Personal Care + Closures pipeline: selected continued post-2024 Beauty + Home ~$1.25-1.35B revenue (~35%+; Fragrance + Skincare + Color Cosmetics + Personal Care + Home Care + Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon customers); selected Closures ~$0.55-0.60B revenue (~16%+; Food + Beverage + Sports Drink). President + CEO Stephan Tanda since 2018 (~7-year tenure); CFO Vanessa Kanu. Capital position: ~$1.80 aggregate annual dividend (~30%+ aggregate payout ratio; ~1.0-1.4% aggregate dividend yield; ~32+ year dividend increase track record); ~$50-150M aggregate FY2025 buybacks; aggregate capital return ~$170-275M FY2025; net leverage ~1.0-1.5x Net Debt/EBITDA; investment-grade A3/A- credit rating; ~66-68M diluted shares; weighted average debt maturity ~6-7 years. FY2026 thesis: Pharma Drug Delivery + Active Material Science pipeline + Beauty + Home + Personal Care + Closures pipeline + post-2024 GLP-1 Auto-Injector + Pre-filled syringe boom + Pediatric Naloxone Nasal Spray + ~32+ year dividend increase track record + ~$130-150B global Pharma Dispensing TAM. Risks: Bemis + Berry Global (post-2024 Amcor merger pending) + Amcor + Sealed Air + Silgan Holdings + Crown Holdings + Becton Dickinson + West Pharmaceutical Services + Albea competitive displacement + post-2024 GLP-1 Auto-Injector + Pre-filled syringe demand cycle considerations + Inhalation + Nasal Spray prescription cycle considerations + Estée Lauder + L'Oréal + Procter & Gamble + Unilever + Coty + Avon customer concentration considerations + Federal Reserve interest rate cycle considerations + post-2018 Stephan Tanda CEO succession planning considerations.